Enzo Biochem (NYSE:ENZ) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
Enzo Biochem (NYSE:ENZ) posted its earnings results on Tuesday. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03, Bloomberg Earnings reports. Enzo Biochem had a net margin of 2.49% and a negative return on equity of 34.02%. The firm had revenue of $20.92 million during the quarter.
Shares of ENZ traded down $0.05 during trading hours on Wednesday, hitting $3.32. The stock had a trading volume of 689 shares, compared to its average volume of 97,871. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.12 and a current ratio of 5.61. The firm has a 50-day moving average price of $3.46 and a 200 day moving average price of $3.51. Enzo Biochem has a fifty-two week low of $2.32 and a fifty-two week high of $4.46.
In related news, major shareholder Discovery Fund Lp Harbert purchased 32,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was bought at an average price of $3.07 per share, with a total value of $99,775.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Harbert Management Corp purchased 9,644 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was bought at an average cost of $3.64 per share, with a total value of $35,104.16. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 64,944 shares of company stock valued at $204,647. Company insiders own 9.40% of the company’s stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.